

10-2018

Androgen decline and outcome in castration resistant prostate cancer(mCRPC) patients treated with docetaxel (Doc), prednisone1/-bevacizumab (B)


C. J. Ryan
Masonic Cancer Center

S. Dutta
Duke University

W. Kelly
Thomas Jefferson University

M. J. Morris
Medicine, Memorial Sloan-Kettering Cancer Center

M-E. Taplin
Follow this and additional works at: <https://jdc.jefferson.edu/medoncfp>
Dana-Farber Cancer Institute

 Part of the **Oncology Commons**

Let us know how access to this document benefits you
See next page for additional authors

Recommended Citation

Ryan, C. J.; Dutta, S.; Kelly, W.; Morris, M. J.; Taplin, M-E.; and Halabi, S., "Androgen decline and outcome in castration resistant prostate cancer(mCRPC) patients treated with docetaxel (Doc), prednisone1/-bevacizumab (B)" (2018). *Department of Medical Oncology Faculty Papers*. Paper 116.
<https://jdc.jefferson.edu/medoncfp/116>

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's [Center for Teaching and Learning \(CTL\)](#). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Department of Medical Oncology Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.

Authors

C. J. Ryan, S. Dutta, W. Kelly, M. J. Morris, M-E. Taplin, and S. Halabi

816P Androgen decline and outcome in castration resistant prostate cancer (mCRPC) patients treated with docetaxel (Doc), prednisone +/- bevacizumab (B)

C.J. Ryan¹, S. Dutta², W. Kelly³, M.J. Morris⁴, M-E. Taplin⁵, S. Halabi⁶

¹Division of Hematology, Oncology and Transplantation, Masonic Cancer Center, Minneapolis, MN, USA, ²Department of Biostatistics and Bioinformatics, Duke University, Durham, NC, USA, ³Medicine, Thomas Jefferson University, Philadelphia, PA, USA, ⁴Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA, ⁵Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA, USA, ⁶Biostatistics and Bioinformatics, Duke University, Durham, NC, USA

Background: Androgen levels are associated with overall survival (OS) in mCRPC. Doc impairs microtubules and has AR inhibitory effects. This analysis evaluates change in androgen levels (Testosterone (T), Androstenedione (A) and DHEA (D) and outcome in Doc-treated mCRPC patients.

Methods: Data from 1,050 men treated on CALGB 90401 with Doc, prednisone and either B or placebo were used. Pre-treatment, 6 week and progression serum assays for T, A and D were performed via tandem Liquid Chromatography-Mass Spectrometry (LC-MS/MS). Ratio of change in androgen (6 week value /baseline value) was calculated. Decline was further evaluated as high or low (> or < median decline for all patients). The logistic regression and proportional hazards models were used to assess the prognostic significance of changes in T, A, and D in predicting PSA response, PFS and OS adjusting for known prognostic factors.

Results: Median values for baseline T, A, and, D were 1.0, 13.5 and 8.1, ng/dL respectively, while androgen levels at 6 weeks were 0.64, 7.0 and 6.8, ng/dL respectively. At 6 weeks a decline in all three androgens was observed. The ratio of 6weeks/baseline in T, A and D were 0.93, 0.56 and 0.86, respectively. There was interaction between levels of T decline and treatment arm (p-value=0.047). Among 291 patients with high levels of T decline, those who also received B were more likely to experience a $\geq 50\%$ decline in PSA (87%) compared to those who did not receive B (67%). Associations between androgen decline and PFS were NS. In multivariable analysis adjusting for prognostic factors, the hazard ratio (HR) for OS demonstrated that decline in T at 6-weeks/baseline was associated with longer OS, HR 1.02 (95% CI 1.01, 1.03 p = 0.001). Median OS for low T change (ratio ≥ 0.93) is 20.9 mos vs 26.3 mos for high T change (<0.93).

Conclusions: Patients treated with Doc who experience a greater drop in T on therapy experience a significantly longer OS and higher rate of PSA decline but no effect on PFS. B and androgen decline may confer interacting beneficial effects. Data are consistent with the favorable prognostic significance of higher serum androgens in the CRPC setting and reflecting the potential effect of Doc on AR signalling.

Clinical trial identification: NCT00110214.

Legal entity responsible for the study: Alliance for Clinical Trials in Oncology.

Funding: National Cancer Institute: R21 CA195424-01, U10CA180821, U10CA180882.

Disclosure: C.J. Ryan: Consulting fees: Sanofi. All other authors have declared no conflicts of interest.